US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

491.81

+15.723.30%

Number of Gainers:4

Number of Losers:- -

Number of Flat:- -

PE:- -

High:507.02

Open:483.01

Low:482.63

Close:476.09

Volume:10.38M

Turnover:271.92M

Market Cap:11.10B

Float Cap:10.39B

Loading ...

Editas Medicine Initiated at Buy by Ladenburg Thalmann

Editas Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Editas Medicine Director Ellinor Patrick Thomas II Files Initial Beneficial Ownership Statement

Intellia Grants Inducement RSUs for 38,200 Shares to Eight New Employees

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)

Editas Medicine, Inc. Expected to Post a Loss of 27 Cents a Share - Earnings Preview

Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)

CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration

Oculis Q2 Net Loss Narrows Despite Higher Expenses

Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit

Intellia Therapeutics, INC. Reports Results for the Quarter Ended June 30 - Earnings Summary

Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens

Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million

Intellia Therapeutics Q2 Net Income USD -106.634 Million

Intellia Therapeutics Q2 Basic EPS USD -0.8

THOMSON REUTERS

Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)

Editas Medicine Strengthens Board With New Cardiology Director

Editas Medicine Q2 Net Loss Narrows and Beats Estimates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":491.81247,"timestamp":1787342399999,"preClose":476.09332,"halted":0,"volume":10380296,"delay":0,"changeRate":0.033017,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":15.719147,"latestTime":"08-21 16:00:00 EDT","open":483.00705,"high":507.0229,"low":482.62756,"amount":271917693.921845,"amplitude":0.051241,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.9206,"peRate":-10.529407,"turnoverRate":0.023735,"increases":4,"decrements":0,"flats":0,"marketCap":11100480736,"floatMarketCap":10393482176},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":507.0229,"amplitude":0.051241,"preClose":476.09332,"low":482.62756,"pbRate":"2.9206","latestPrice":491.81247,"volume":10380296,"delay":0,"open":483.00705,"prevYearClose":431.70972,"prevWeekClose":444.6557,"prevMonthClose":405.9402,"prevQuarterClose":517.3469,"fiveDayClose":444.6557,"twentyDayClose":398.2596,"sixtyDayClose":482.6405,"secType":"PLATE","market":"US","turnoverRate":0.023735,"peRate":-10.529407,"marketCap":11100480736,"floatMarketCap":10393482176,"timestamp":1787342399999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":4,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660467429","title":"Editas Medicine Initiated at Buy by Ladenburg Thalmann","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467429","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467429?lang=en_us&edition=fundamental","pubTime":"2026-08-18 20:58","pubTimestamp":1787057880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EDIT/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658593567","title":"Editas Medicine, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658593567","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658593567?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:59","pubTimestamp":1786363182,"startTime":"0","endTime":"0","summary":"Editas Medicine, Inc. reports results for the quarter ended June 30 - Earnings SummaryEditas Medicine, Inc.EDIT.OQreported a quarterly adjusted loss of 15 cents per share for the quarter ended June 30","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4470RH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","EDIT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657262941","title":"Editas Medicine Director Ellinor Patrick Thomas II Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2657262941","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657262941?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:16","pubTimestamp":1786137389,"startTime":"0","endTime":"0","summary":"Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statementEditas Medicine filed a Form 3 showing director Ellinor Patrick Thomas II as a reporting owner, dated Aug. 6.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Editas Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 07, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL63cxB4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657257916","title":"Intellia Grants Inducement RSUs for 38,200 Shares to Eight New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2657257916","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657257916?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132885,"startTime":"0","endTime":"0","summary":"Intellia grants inducement RSUs for 38,200 shares to eight new employeesIntellia Therapeutics awarded time-based restricted stock units covering 38,200 shares to eight new employees on Aug. 1, 2026.On","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL84Gpfs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU1861559042.SGD","IE00BKPKM429.USD","LU2210149790.SGD","LU2210150020.SGD","BK4556","LU0314104364.USD","BK4139","SG9999014005.SGD","NDAQ","BK4585","BK4588","IE00B64PRP62.GBP","BCDF","SG9999014013.SGD","SG9999014039.USD","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4112","BK4535","NTLA","LU1861558580.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657962653","title":"Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657962653","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657962653?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:01","pubTimestamp":1786132860,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Aug.  07, 2026  (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/07/3341377/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861559042.SGD","LU1861558580.USD","NTLA","BK4139","BK4556","BK4585","LCLG","BK4588","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657433647","title":"Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana Health (ASTH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657433647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657433647?lang=en_us&edition=fundamental","pubTime":"2026-08-07 23:50","pubTimestamp":1786117814,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM), OmniAb (OABI) and Astrana ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beam-therapeutics-beam-omniab-oabi-and-astrana-health-asth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beam-therapeutics-beam-omniab-oabi-and-astrana-health-asth-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4585","BK4505","BK4581","LU0128526141.USD","BK4121","OABI","LABU","ASTH","BK4139","BK4588","BK4556","BK4137","XBI","BK4196","BK4535","LU0029874061.USD","BK4611","HCSG","BEAM","LU1861559042.SGD","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657644491","title":"Editas Medicine, Inc. Expected to Post a Loss of 27 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657644491","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657644491?lang=en_us&edition=fundamental","pubTime":"2026-08-07 22:33","pubTimestamp":1786113186,"startTime":"0","endTime":"0","summary":"Editas Medicine, Inc. <EDIT.OQ> expected to post a loss of27cents a share - Earnings PreviewEditas Medicine, Inc.EDIT.OQEDIT.Ois expected to  show a fall in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4441OR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657092661","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Intellia Therapeutics (NTLA), Haemonetics (HAE) and Nuvation Bio (NUVB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657092661","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657092661?lang=en_us&edition=fundamental","pubTime":"2026-08-07 07:00","pubTimestamp":1786057226,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intellia Therapeutics (NTLA), Haemonetics (HAE) an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-intellia-therapeutics-ntla-haemonetics-hae-and-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-intellia-therapeutics-ntla-haemonetics-hae-and-nuvation-bio-nuvb-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","HAE","LU1169590202.USD","BK4007","BK4588","NUVB","IE00B19Z6F94.USD","BK4535","XBI","LU0205193047.USD","BK4198","LU0128526141.USD","BK4556","NTLA","LU0205194284.USD","BK4581","IE0034390439.USD","LU0029874061.USD","LU1861559042.SGD","LU1169589451.USD","IE00BLDYK493.USD","XLV","BK4139","LABU","LU1861558580.USD","LU0012050646.USD","LU0106261612.USD","BK4585","IE00B64QTZ34.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669586","title":"CytomX Q2 Revenue Misses, Partly Hurt by Lower Research Activities in the Astellas Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669586","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657669586?lang=en_us&edition=fundamental","pubTime":"2026-08-07 06:05","pubTimestamp":1786053911,"startTime":"0","endTime":"0","summary":"CytomX Q2 revenue misses, partly hurt by lower research activities in the Astellas collaborationOverviewUS oncology biopharma's Q2 revenue declined sharply and missed analyst expectationsCompany expan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431P3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505439.SGD","LU1718418525.SGD","BK4585","NTLA","LU2596442595.SGD","LU2125154778.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0306806265.USD","LU1883839398.USD","BK4588","LU0061475181.USD","BK4556","LU1074936037.SGD","LU1868836591.USD","VYGR","FTXH","LU2125154935.USD","LU0985481810.HKD","LU1989771016.USD","LU0096364046.USD","LU1571399168.USD","LU1430594728.SGD","BK4563","IHE","LU1291159041.SGD","LU1585245621.USD","IE0002141913.USD","BMY","LU0321505868.SGD","LU0114720955.EUR","LU1868837136.USD","BK4559","LU1323610961.USD","IE00BSNM7G36.USD","RLAY","LU1868836757.USD","LU0456855351.SGD","BK4532","LU2242646821.SGD","LU1861558580.USD","LU0225771236.USD","LU1983299246.USD","CTMX","LU0225284248.USD","LU1670711040.USD","LU0868494617.USD","LU0267386448.USD","LU2360032135.SGD","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657668929","title":"Oculis Q2 Net Loss Narrows Despite Higher Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2657668929","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657668929?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:32","pubTimestamp":1786048350,"startTime":"0","endTime":"0","summary":"Oculis Q2 net loss narrows despite higher expensesOverviewBiopharma firm's Q2 net loss narrowed yr/yr as operating expenses roseOperating expenses increased, mainly from higher headcount and share-bas","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","LU1861559042.SGD","ALGS","CRSP","BK4611","OCS","ARKG","BK4556","BK4585","BK4007","BK4505","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657740","title":"Lineage Cell Therapeutics Q2 Revenue Falls but Posts Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657740","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657740?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:11","pubTimestamp":1786047092,"startTime":"0","endTime":"0","summary":"Lineage Cell Therapeutics Q2 revenue falls but posts profitOverviewUS cell therapy developer's Q2 revenue declined yr/yr due to lower collaboration revenueQ2 net income reached $1.5 mln, reversing a l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4431DC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNAC","LU1861558580.USD","BK4535","NTLA","BK4556","BK4585","LCTX","LU1861559042.SGD","BK4139","DTIL","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657632469","title":"Intellia Therapeutics, INC. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632469","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632469?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023128,"startTime":"0","endTime":"0","summary":"INTELLIA THERAPEUTICS, INC. reports results for the quarter ended June 30 - Earnings SummaryINTELLIA THERAPEUTICS, INC.NTLA.OQreported a quarterly adjusted loss of 80 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431W0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4556","LU1861559042.SGD","LU1861558580.USD","NTLA","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657560633","title":"Intellia Therapeutics Q2 Collaboration Revenue Falls, Net Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2657560633","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657560633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015252,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Q2 collaboration revenue falls, net loss widensOverviewU.S. gene editing firm's Q2 collaboration revenue fell yr/yr due to lower Regeneron revenueQ2 net loss widened from prior y","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430JC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTLA","IBBQ","LU2468319806.SGD","LU1861558580.USD","BBH","LU2106854487.HKD","LU0053666078.USD","LU0109394709.USD","LU2362541513.USD","LU2023250504.SGD","BK4535","LU2362540622.SGD","TBXU","LU2237438978.USD","LU0882574055.USD","LU2089984988.USD","LU1861559042.SGD","REGN","BK4139","LU0823416689.USD","LU0114720955.EUR","LU2362541273.HKD","ARKG","BK4556","LU1974910355.USD","LU0320765992.SGD","LU0823434583.USD","LU0058720904.USD","IBB","LU0889565916.HKD","BK4588","LU0823434740.USD","BK4585","BK4611","LU1917777945.USD","CRSP","EDIT","LU0289739699.SGD","PGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638109","title":"Intellia Q2 FY26 Net Loss Widens to $106.63 Million; Revenue Falls to $7.66 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638109","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638109?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:09","pubTimestamp":1786014575,"startTime":"0","endTime":"0","summary":"Intellia Q2 FY26 net loss widens to $106.63 million; revenue falls to $7.66 millionIntellia posted a GAAP net loss of USD 106.63 million, widening from USD 101.26 million a year earlier; loss per shar","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL3QMBnk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","TBXU","BK4139","LU0823434740.USD","LU0823434583.USD","LU2089984988.USD","LU0823416689.USD","BK4556","IBBQ","BK4535","LU1861559042.SGD","REGN","LU0289739699.SGD","LU0889565916.HKD","NTLA","LU0053666078.USD","LU2237438978.USD","LU1861558580.USD","LU2362541273.HKD","BBH","LU2023250504.SGD","LU2106854487.HKD","IBB","LU0114720955.EUR","LU2362541513.USD","LU0882574055.USD","LU1917777945.USD","LU0058720904.USD","LU0320765992.SGD","BK4585","LU2468319806.SGD","LU2362540622.SGD","BK4588","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657638326","title":"Intellia Therapeutics Q2 Net Income USD -106.634 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657638326","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657638326?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014063,"startTime":"0","endTime":"0","summary":"BRIEF-Intellia Therapeutics Q2 Net Income USD -106.634 MillionAug 06 (Reuters) - Intellia Therapeutics Q2 collaboration revenue USD 7.659 million.Q2 basic EPS USD -0.8Q2 operating expenses USD 120.419 millionQ2 operating income USD -112.76 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXV9XFXJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4139","BK4588","NTLA","BK4556","BK4585","BK4535","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680446","title":"Intellia Therapeutics Q2 Basic EPS USD -0.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680446","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680446?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLXV9XFXJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1861559042.SGD","BK4139","NTLA","BK4535","BK4556","LU1861558580.USD","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687268","title":"Analysts Are Bullish on Top Healthcare Stocks: MannKind (MNKD), Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687268","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687268?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:40","pubTimestamp":1786012820,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MannKind (MNKD), Disc Medicine (IRON) and Editas Med...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-mannkind-mnkd-disc-medicine-iron-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-mannkind-mnkd-disc-medicine-iron-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0053671581.USD","BK4584","IRON","MNKD","EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657508570","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657508570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657508570?lang=en_us&edition=fundamental","pubTime":"2026-08-06 09:20","pubTimestamp":1785979213,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medici...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-ginkgo-bioworks-holdings-dna-exelixis-exel-and-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-ginkgo-bioworks-holdings-dna-exelixis-exel-and-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","HCSG","BK4588","BK4139","XLV","BK4532","BK4121","XBI","BK4556","BK4109","BK4581","EXEL","LU0029874061.USD","EDIT","LU0128526141.USD","BK4137","LABU","DNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657757962","title":"Editas Medicine Strengthens Board With New Cardiology Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2657757962","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657757962?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:07","pubTimestamp":1785964075,"startTime":"0","endTime":"0","summary":"An announcement from Editas Medicine ( ($EDIT) ) is now available. On August 3, 2026, Editas Medicine director Elliott Levy, M.D., resigned from th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-medicine-strengthens-board-with-new-cardiology-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-medicine-strengthens-board-with-new-cardiology-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT","BK4139","BK4556"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657752095","title":"Editas Medicine Q2 Net Loss Narrows and Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2657752095","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657752095?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:11","pubTimestamp":1785960676,"startTime":"0","endTime":"0","summary":"Editas Medicine Q2 net loss narrows and beats estimatesOverviewUS gene editing firm's Q2 net loss narrowed and beat analyst expectationsCollaboration and other R&D revenue more than tripled yr/yr to $","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4421AG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU1861558580.USD","EDIT","CRSP","BK4556","ARKG","TRDA","BK4611","BK4139","KYMR","BK4585","LU1861559042.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}